Clinical Trial Search

Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8 — 0.5; 0.2 Percent predicted of FEV1 — p== 0.5846

Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 0; 0 participants

Primary: Mean Percentage of Heavy Drinking Days — 39; 42; 28 percentage of heavy drinking days — p=0.018

Primary: Primary Efficacy Analysis: Number of Randomized Subjects With Tympanogram Normalization at 6 Weeks — 73; 10 Participants

Primary: Progression-free Survival (PFS) — 13.3; 9.9 Months

Primary: IOL A-constant at 3 Months at Each Site — 119.23; 119.18; 118.86; 118.93 unitless

Primary: Change From Baseline in Overall Macpherson Modification of the Lobene Stain Index (MLSI) at 8 Weeks. — -0.32; -0.47; -0.38; -0.40 Score on a scale — p=0.6499

Primary: % Vital Bone Formation (Histological) — 31.27; 36.21 % vital bone

Primary: Hospital / Emergency Visits Per 60 Days (no. of Events/Follow-up Days) — .68; .53 events per day — p=0.415

Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 10; 0 participants

Primary: The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit — 12.8; 14.4; 17.6; 17.1 Number of Inflammatory Lesions — p=0.4344

Primary: Percentage of Participants With Clinically Significant Prostate Cancer — 36.6; 34.6; 36.6; 43.7 percentage of participants with csPCa

Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months

Primary: Success Rates of the Procedure — 8; 14; 16; 11 Participants

Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days